186Re-Rhenium Etidronate (HEDP)

186Re-Rhenium Etidronate (HEDP)

Description186Re-Rhenium Etidronate (commonly referred to as 186Re-HEDP, hydroxyethylidene diphosphonate, or 186Re-Etidronate) is a radiopharmaceutical developed by Mallinckrodt for palliating bone pain caused by metastatic bone cancer. This innovative formulation was initially approved and launched in Switzerland and Greece. However, despite its potential, the New Drug Application (NDA) submitted to the… Continue Reading…

177Lu-Oxodotreotide

177Lu-Oxodotreotide

Description 177Lu-Oxodotreotide (also known as 177Lu-Lutathera®, 177Lu-DOTATATE, and Lutetium-177 dotatate) is a somatostatin analogue developed for the treatment of neuroendocrine tumors (NETs). It was the first 177Lu-labeled molecule to receive marketing authorization. The drug was originally developed by Biosynthema, which was acquired by Advanced Accelerator Applications (AAA) in 2010. The… Continue Reading…

177Lu-EDTMP

177Lu-EDTMP

What is 177Lu-EDTMP? 177Lu-EDTMP (Lutetium-177 ethylenediaminetetramethylene phosphonate) is a radiopharmaceutical therapy developed for bone pain palliation in cancer patients, specifically those with bone metastases, such as from prostate cancer. It serves as an alternative to 153Sm-EDTMP (Lexidronam), commonly known as Quadramet®, which was widely used for the same indication. Although… Continue Reading…

169Er-Erbium Citrate

169Er-Erbium Citrate

What is 169Er-Erbium Citrate? 169Er-Erbium Citrate is a specialized radiopharmaceutical therapy designed for isotopic radiation synovectomy, particularly targeting small joints such as those in the hands and feet. This treatment leverages the therapeutic benefits of radioactive isotopes to alleviate symptoms of joint-related conditions. Clinical Applications of 169Er-Erbium Citrate This therapy… Continue Reading…

166Ho-Chitosan

166Ho-Chitosan

Overview166Ho-Chitosan, also known as DW166-HC, is an innovative radiopharmaceutical drug designed for targeted cancer therapy. Commercially available under the brand name Milican in South Korea, it was developed by Dong Wha Pharmaceuticals and launched in August 2001. This therapeutic agent offers a novel approach for treating hepatocellular carcinoma (HCC), leveraging… Continue Reading…

166Ho-QuiremSpheres

166Ho-QuiremSpheres

Description 166Ho-QuiremSpheres (also known as 166Ho-PLLA-MS) is a medical device developed at the University Medical Center Utrecht in the Netherlands. The product consists of microparticles loaded with the radioactive isotope Holmium-166. These microparticles are created by activating 165Ho pre-loaded poly-L-lactic acid (PLLA) particles with neutron flux in a reactor, using… Continue Reading…

153Sm-Oxabiphor

153Sm-Oxabiphor

Description 153Sm-Oxabiphor, also known as Samarium-153 oxa-bis(ethylenedithio)tetramethylphosphonium acid, is a radiopharmaceutical used for pain relief in patients with osteoblastic skeletal metastases. These metastases typically show up on a 99mTc-bisphosphonate bone scan. 153Sm-Oxabiphor was developed to bypass existing patents and territory restrictions, making it more accessible in certain regions. The drug… Continue Reading…

153Sm-Lexidronam (Quadramet®)

153Sm-Lexidronam (Quadramet®)

Overview 153Sm-Lexidronam pentasodium, also known as 153Sm-Samarium Ethylene Diamine Tetramethylene Phosphoric Acid (EDTMP) or Quadramet®, is a therapeutic radiopharmaceutical used primarily for palliating bone pain in patients with multiple osteoblastic skeletal metastases, which are detected using 99mTc-bisphosphonate bone scans. This agent was initially developed by Cytogen, leveraging technology licensed from… Continue Reading…

133Xe-Xenon (Gas)

133Xe-Xenon (Gas)

Description133Xe-Xenon serves as a diagnostic radiopharmaceutical. It is primarily used as a gas (5% diluted in carbon dioxide) for evaluating pulmonary function and lung imaging. Additionally, a saline solution form allows its use in cerebral blood flow assessment. Clinical ApplicationsThe gas form of 133Xe-Xenon helps in lung ventilation imaging. Typical… Continue Reading…

131I-Weimeisheng

131I-Weimeisheng

Manufacturer and Development131I-Weimeisheng, also known as 131I-Tumor Necrosis Therapy monoclonal antibody (mAb) injection, is a radiolabeled chimeric antibody. It was originally developed at the University of Southern California and later commercialized in China by Shanghai Meien Biotechnology and the China Isotope & Radiation Corporation (CIRC). Classified as a ‘me-too plus’… Continue Reading…